Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fingerprick autologous blood
- Development stage
- Unknown
- Lead developer
- Moorfields Eye Hospital
- Modality
- Cell Therapies
- Administration
- Ophthalmic, Topical
01
Overview
Fingerprick autologous blood (FAB) is a bedside biologic therapy that utilizes a patient's own whole blood, obtained via a lancet finger prick, for the treatment of ocular and oral surface disorders. Developed as a simpler and more cost-effective alternative to autologous serum (AS) eye drops, FAB does not require venesection, centrifugation, or specialized cold chain storage. The therapeutic effect is mediated by the delivery of endogenous growth factors—including epidermal growth factor (EGF), transforming growth factor beta (TGF-β), and hepatocyte growth factor (HGF)—as well as anti-inflammatory mediators and vitamins naturally present in whole blood. These components mimic the complex biochemical environment of natural tears and saliva, facilitating epithelial cell proliferation, survival, and wound healing. FAB is primarily investigated for severe dry eye disease, meibomian gland dysfunction (MGD), persistent corneal epithelial defects, and xerostomia (dry mouth).
- Other names
- Finger-prick Autologous BloodWhole fresh fingerprick bloodAutologous whole blood
Beyond the preview
Go deeper on fingerprick autologous blood.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fingerprick autologous blood.